TerrAscend Corp. (OTCMKTS:TRSSF – Get Rating) has been given a consensus rating of “Moderate Buy” by the ten analysts that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $3.57.
Several equities research analysts recently commented on the stock. Canaccord Genuity Group assumed coverage on shares of TerrAscend in a research report on Monday, September 12th. They issued a “buy” rating and a C$4.25 price objective on the stock. Cowen decreased their price objective on shares of TerrAscend from $9.00 to $4.50 in a research report on Monday, August 15th. Stifel Nicolaus decreased their price objective on shares of TerrAscend from C$6.00 to C$5.50 in a research report on Friday, August 12th. Cantor Fitzgerald decreased their price objective on shares of TerrAscend from $2.85 to $2.15 and set a “neutral” rating on the stock in a research report on Friday, October 28th. Finally, Craig Hallum lowered shares of TerrAscend from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $7.50 to $2.00 in a research report on Friday, August 12th.
TerrAscend Price Performance
Shares of OTCMKTS TRSSF opened at $1.78 on Tuesday. The firm has a market capitalization of $448.31 million and a P/E ratio of -1.33. TerrAscend has a one year low of $1.21 and a one year high of $6.76. The company’s fifty day moving average is $1.55 and its two-hundred day moving average is $2.29. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.37 and a current ratio of 0.66.
TerrAscend Company Profile
TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. It produces and distributes hemp-derived wellness products to retail locations; and manufactures cannabis infused artisan edibles. The company also operates three retail dispensaries under the Apothecarium brand name in California and Pennsylvania.
- Get a free copy of the StockNews.com research report on TerrAscend (TRSSF)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for TerrAscend Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TerrAscend and related companies with MarketBeat.com's FREE daily email newsletter.